Efficacy of La Roche Posay Routine in the Management of Facial Post Inflammatory Hyperpigmentation (PIHP)

Inclusion Criteria: * Fitzpatrick skin phototype: III to VI; * Moderate to severe PIHP due to acne (score PAHPI \> 10); * Subjects with mild acne on the face (GEA = 2); * ≤ 4 inflammatory lesions total (non-inflammatory lesions could be 0) Exclusion Criteria: * Subjects with symptoms of COVID-19 (moderate fever, dry cough and other symptoms described by the World Health Organization); * Subjects with a temperature above 37.5 °C; * COVID-19 positive patients; * For women: pregnant or nursing woman or woman planning to get pregnant during the study; * Cutaneous pathology on the study zone (eczema, etc); * Use of topical or systemic treatment (for ex: treatment of acne) during the previous weeks liable to interfere with the assessment of the cutaneous acceptability/efficacy of the study product; * Subject with make-up products on the day of the visit at the laboratory; * Acne and depigmenting treatment (topical or systemic): * Topical treatment claiming depigmenting effect of the face: within the last month, * Facial procedures: within the last 3 months, * Systemic retinoid: within the last 6 months. * Cosmetic product for non-comedogenicity within the last 2 weeks; * Subjects treated for PIHP within the past 3 months with either a cosmetic product or a drug; * Any change in hormonal treatment (including contraceptive) during the three previous months of the study; * Subject having undergone a surgery under general anesthesia within the previous month; * Excessive exposure to sunlight or UV-rays within the previous month; * Subject enrolled in another clinical trial during the study period.